None listed
Conditions
Brief summary
This study investigates whether probucol, a lipid-lowering medication, is associated with reduced risk of dementia in older adults. Using Japan's comprehensive healthcare database covering over 27 million people from 2014-2023, we will compare dementia rates between older adults prescribed probucol versus those prescribed statins. This research addresses a critical gap in dementia prevention research by examining whether probucol's demonstrated brain-protective effects in laboratory studies translate to real-world clinical benefits. The findings could inform clinical guidelines for medication selection in older adults at risk for cognitive decline.
Interventions
This retrospective cohort examines exposure to probucol (a lipid-lowering medication) compared to statin medications in adults aged >=50 years using the Japan Medical Data Centre (JMDC) claims database (2014-2023).
Data collected: demographic characteristics, medical history, comorbidities, medication use, and dementia diagnoses recorded in claims data.
Participant involvement: none; all data are de-identified and extracted directly from medical records within the JMDC database.
Duration of obs
This retrospective cohort examines exposure to probucol (a lipid-lowering medication) compared to statin medications in adults aged >=50 years using the Japan Medical Data Centre (JMDC) claims database (2014-2023). Data collected: demographic characteristics, medical history, comorbidities, medication use, and dementia diagnoses recorded in claims data. Participant involvement: none; all data are de-identified and extracted directly from medical records within the JMDC database. Duration of observation: from the date of first eligible prescription (index date) until first dementia diagnosis, death, disenrollment, or end of study period (31 December 2023).
Sponsors
Curtin University
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
• Adults aged 50 years or older • At least two prescriptions for probucol or statin medication during the study period (2014–2023) • Minimum of two filled prescriptions to ensure sustained exposure • Continuous enrolment in the JMDC database for at least 12 months prior to the first eligible prescription
Exclusion criteria
• Prior diagnosis of dementia before index prescription date • Prescriptions for study medications within 12 months of database entry • Dementia-related diagnostic codes within 12 months of baseline
Outcome results
None listed